fda approved glp 1 Eli Lilly GLP-1 pill Foundayo for obesity New GLP-1 Pill Foundayo (Orforglipron)

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

Taha MB, Yahya T, Satish P, et al

Expel air bubbles back into the vial and re-read the meniscus before withdrawing the needle

A gradual taper - reducing the dose in steps over several weeks or months - may help ease the transition

Lemme does use the same 400 mg dose as the study